Back to results
US 11,285,197 B2Granted
Mesothelin vaccines and model systems
AssigneeThe Johns Hopkins University
InventorsElizabeth A. Jaffee, Tzyy-Choou Wu, Chien-Fu Hung, Ralph Hruban
Life of this patent
Estimating the term…
Abstract
Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
Claims9
An immunogenic composition which induces a CD8™ T cell or CD4″ T cell response, comprising:
- a polypeptide comprising a human leukocyte antigen (HLA) Class I- or Class II restricted mesothelin;
- and
- a carrier for stimulating a CD8″ T cell or CD4* T cell immune response, wherein the carrier is selected from the group consisting of:
- a) a protein that is fused to the polypeptide, said protein selected from the group consisting of CD40, CD40 ligand, OX-40, OX-40 ligand, CTLA-4 antagonist, and GM-CSF;
- and
- (b) a bacterial cell that is transformed to express the polypeptide;
- and
- (c) an antigen presenting cell on whose surface the polypeptide is bound.
5 more elements
Dependencies are inferred from the claim text.